Tag: Obesity
Tirzepatide Yields Sustained Weight Reduction in Obesity, Prediabetes
Three years of tirzepatide also reduced risk for progression to type 2 diabetes compared with placebo
Expanding Access to Obesity Medications Could Avert 42,000 Deaths/Year
Impact of expanding access to GLP-1 receptor agonists, dual gastric inhibitory polypeptide and GLP-1 receptor agonists quantified
Semaglutide Beneficial for People With Obesity, Knee Osteoarthritis
Semaglutide results in greater reductions in body weight and pain related to knee osteoarthritis than placebo
Trends in Obesity Treatment Show Surge in GLP-1 RAs, Drop in Surgeries
Authors say clinicians should evaluate trade-offs between pharmaceutical and surgical management of obesity
Preschool Outdoor Play Time Tied to Lower Risk for Later Obesity
Findings seen for outdoor play at age 2.5 years and subsequent body mass index at age 7 years
Metabolic-Bariatric Surgery Tied to Reduced Risk for Pancreatic Cancer in Those With Obesity
Reduced risk was more pronounced in those with type 2 diabetes, but was also seen in those without T2D
Body Roundness Index Trajectory Tied to Risk for Cardiovascular Disease
In a longitudinal cohort, middle-aged and older Chinese people with moderate-stable and high-stable BRI had increased risk for CVD
Metabolic Surgery Is Renoprotective in Patients With Obesity, CKD
Metabolic surgery linked to lower risk for progression of kidney impairment compared with GLP-1RA
Semaglutide Beneficial for Hidradenitis Suppurativa in Patients With Obesity
Semaglutide added to standard treatments yields improvement in quality of life, reduction in flares
Prevalence of Obesity 40.3 Percent in U.S. From August 2021 to August 2023
No significant change in prevalence of obesity seen from 2013-2014 to August 2021-2023, but prevalence of severe obesity increased
